Skip to main content

Advertisement

SpringerLink
Log in

LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p

  • Original Paper
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

This study revealed the prognostic significance of long non-coding RNA (lncRNA) CCDC144NL-AS1 in NSCLC patients and discussed the effect and mechanism of proliferation, migration, and invasion of non-small cell lung cancer (NSCLC) cells. 128 pairs of NSCLC tissues and paracancerous tissues were collected, and qRT-PCR was used to detect the differential expression of lncRNA CCDC144NL-AS1 in all tissues and cells lines. Kaplan–Meier analysis and Cox proportional hazards model analysis were used to estimate the prognostic value of lncRNA CCDC144NL-AS1. CCK-8 and Transwell assays confirmed the effect of lncRNA CCDC144NL-AS1 on the proliferation, migration, and invasion of NSCLC. Bioinformatics was used to predict the microRNAs that lncRNA CCDC144NL-AS1 might bind to miR-490-3p. The regulation of lncRNA CCDC144NL-AS1 on miR-490-3p was verified by luciferase activity assay with wide type or mutation. The expression of lncRNA CCDC144NL-AS1 was enhanced in both NSCLC tissues and cell lines. Patients with overexpression of lncRNA CCDC144NL-AS1 have a poor prognosis, and lncRNA CCDC144NL-AS1 is an independent prognostic factor for NSCLC. Increased the relative expression level of lncRNA CCDC144NL-AS1 can promote the proliferation, migration, and invasion of NSCLC cells. LncRNA CCDC144NL-AS1 might target miR-490-3p. LncRNA CCDC144NL-AS1 can be used as an oncogene of NSCLC to predict patient prognosis and promote tumor proliferation, migration, and invasion by targeting miR-490-3p.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Romaszko, A. M., & Doboszyńska, A. (2018). Multiple primary lung cancer: A literature review. Advances in Clinical and Experimental Medicine, 27, 725–730.

    Article  Google Scholar 

  2. Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. Nature, 553, 446–454.

    Article  CAS  Google Scholar 

  3. Jonna, S., & Subramaniam, D. S. (2019). Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update. Discovery Medicine, 27, 167–170.

    PubMed  Google Scholar 

  4. Broderick, S. R. (2020). Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thoracic Surgery Clinics, 30, 215–220.

    Article  Google Scholar 

  5. Valentino, F., Borra, G., Allione, P., & Rossi, L. (2018). Emerging targets in advanced non-small-cell lung cancer. Future Oncology, 14, 61–72.

    Article  CAS  Google Scholar 

  6. Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019). Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nature Reviews. Clinical Oncology, 16, 341–355.

    Article  CAS  Google Scholar 

  7. Proto, C., Ferrara, R., Signorelli, D., Lo Russo, G., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., De Simone, I., Colombo, M. P., Sica, A., Torri, V., & Garassino, M. C. (2019). Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out. Cancer Treatment Reviews, 75, 39–51.

    Article  CAS  Google Scholar 

  8. Ruiz-Cordero, R., & Devine, W. P. (2020). Targeted therapy and checkpoint immunotherapy in lung cancer. Surgical Pathology Clinics, 13, 17–33.

    Article  Google Scholar 

  9. Jarroux, J., Morillon, A., & Pinskaya, M. (2017). History, discovery, and classification of lncRNAs. Advances in Experimental Medicine and Biology, 1008, 1–46.

    Article  CAS  Google Scholar 

  10. Isin, M., & Dalay, N. (2015). LncRNAs and neoplasia. Clinica Chimica Acta, 444, 280–288.

    Article  CAS  Google Scholar 

  11. Wu, T., & Du, Y. (2017). LncRNAs: From basic research to medical application. International Journal of Biological Sciences, 13, 295–307.

    Article  CAS  Google Scholar 

  12. Gupta, C., Su, J., Zhan, M., Stass, S. A., & Jiang, F. (2019). Sputum long non-coding RNA biomarkers for diagnosis of lung cancer. Cancer Biomarkers, 26, 219–227.

    Article  CAS  Google Scholar 

  13. Gao, S., Zhao, Z. Y., Wu, R., Zhang, Y., & Zhang, Z. Y. (2018). Prognostic value of long noncoding RNAs in gastric cancer: A meta-analysis. Oncotargets and Therapy, 11, 4877–4891.

    Article  Google Scholar 

  14. Quan, J., Pan, X., Zhao, L., Li, Z., Dai, K., Yan, F., Liu, S., Ma, H., & Lai, Y. (2018). LncRNA as a diagnostic and prognostic biomarker in bladder cancer: A systematic review and meta-analysis. Onco Targets and Therapy, 11, 6415–6424.

    Article  CAS  Google Scholar 

  15. He, Y., Meng, X. M., Huang, C., Wu, B. M., Zhang, L., Lv, X. W., & Li, J. (2014). Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Letters, 344, 20–27.

    Article  CAS  Google Scholar 

  16. Fan, H., Ge, Y., Ma, X., Li, Z., Shi, L., Lin, L., Xiao, J., Chen, W., Ni, P., Yang, L., & Xu, Z. (2020). Long non-coding RNA CCDC144NL-AS1 sponges miR-143-3p and regulates MAP3K7 by acting as a competing endogenous RNA in gastric cancer. Cell Death & Disease, 11, 521.

    Article  CAS  Google Scholar 

  17. He, J., Guan, J., Liao, S., Wu, Z., Liu, B., Mo, H., & Yuan, Z. (2021). Long noncoding RNA CCDC144NL-AS1 promotes the oncogenicity of osteosarcoma by acting as a molecular sponge for microRNA-490-3p and thereby increasing HMGA2 expression. Onco Targets and Therapy, 14, 1–13.

    Article  CAS  Google Scholar 

  18. Liu, H., Gu, X., Wang, G., Huang, Y., Ju, S., Huang, J., Ju, S., Huang, J., & Wang, X. (2019). Copy number variations primed lncRNAs deregulation contribute to poor prognosis in colorectal cancer. Aging (Albany NY), 11, 6089–6108.

    Article  CAS  Google Scholar 

  19. Li, B., Zhang, F., & Li, H. (2020). miR-1225-5p inhibits non-small cell lung cancer cell proliferation, migration and invasion, and may be a prognostic biomarker. Experimental and Therapeutic Medicine, 20, 172.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Naylor, E. C., Desani, J. K., & Chung, P. K. (2016). Targeted therapy and immunotherapy for lung cancer. Surgical Oncology Clinics of North America, 25, 601–609.

    Article  Google Scholar 

  21. Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019). Biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices. American Society of Clinical Oncology Educational Book, 39, 531–542.

    Article  Google Scholar 

  22. Chen, S., Shi, F., Zhang, W., Zhou, Y., & Huang, J. (2019). miR-744-5p inhibits non-small cell lung cancer proliferation and invasion by directly targeting PAX2. Technology in Cancer Research & Treatment, 18, 1533033819876913.

    CAS  Google Scholar 

  23. Yang, Z. Q., Wu, C. A., & Cheng, Y. X. (2018). Prognostic value of microRNA-133a expression and its clinicopathologic significance in non-small cell lung cancer: A comprehensive study based on meta-analysis and the TCGA database. Oncology Research and Treatment, 41, 762–768.

    Article  CAS  Google Scholar 

  24. Osmani, L., Askin, F., Gabrielson, E., & Li, Q. K. (2018). Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Seminars in Cancer Biology, 52, 103–109.

    Article  CAS  Google Scholar 

  25. Li, Y., Jiang, T., Zhou, W., Li, J., Li, X., Wang, Q., Jin, X., Yin, J., Chen, L., Zhang, Y., Xu, J., & Li, X. (2020). Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nature Communications, 11, 1000.

    Article  CAS  Google Scholar 

  26. Sun, W., Zu, Y., Fu, X., & Deng, Y. (2017). Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncology Reports, 38, 3347–3354.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Qu, C. H., Sun, Q. Y., Zhang, F. M., & Jia, Y. M. (2017). Long non-coding RNA ROR is a novel prognosis factor associated with non-small-cell lung cancer progression. European Review for Medical and Pharmacological Sciences, 21, 4087–4091.

    PubMed  Google Scholar 

  28. Wang, S., Jiang, W., Zhang, X., Lu, Z., Geng, Q., Wang, W., Li, N., & Cai, X. (2020). LINC-PINT alleviates lung cancer progression via sponging miR-543 and inducing PTEN. Cancer Medicine, 9, 1999–2009.

    Article  CAS  Google Scholar 

  29. Zhang, C., Wu, W., Zhu, H., Yu, X., Zhang, Y., Ye, X., Cheng, H., Ma, R., Cui, H., Luo, J., Guan, J., & Chang, X. (2019). Knockdown of long noncoding RNA CCDC144NL-AS1 attenuates migration and invasion phenotypes in endometrial stromal cells from endometriosis†. Biology of Reproduction, 100, 939–949.

    Article  Google Scholar 

  30. Liu, X., He, B., Xu, T., Pan, Y., Hu, X., Chen, X., & Wang, S. (2018). MiR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer. Journal of Cancer, 9, 1218–1230.

    Article  Google Scholar 

  31. Tian, J., Xu, Y. Y., Li, L., & Hao, Q. (2017). MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. American Journal of Translational Research, 9, 1127–1138.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Lu, H., Yang, D., Zhang, L., Lu, S., Ye, J., Li, M., & Hu, W. (2019). Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-β pathway activation. Oncology Letters, 17, 4633–4639.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Xu, Y., Wang, H., Li, F., Heindl, L. M., He, X., Yu, J., Yang, J., Ge, S., Ruan, J., Jia, R., & Fan, X. (2019). Long non-coding RNA LINC-PINT suppresses cell proliferation and migration of melanoma via recruiting EZH2. Frontories in Cell and Developmental Biology, 7, 350.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Lei Zhang and Baihong Chi are contributed equally to this work.

Authors and Affiliations

  1. First Department of Respiratory and Critical Care Medicine, People’s Hospital of Rizhao, Shangdong, 276800, China

    Lei Zhang

  2. Second Department of Respiratory and Critical Care Medicine, People’s Hospital of Rizhao, No. 126 Taian Road, Donggang District, Shangdong, 276800, China

    Baihong Chi

  3. Department of Pharmacy, The Second Hospital of Jilin University, Jilin, 130041, China

    Jin Chai

  4. Department of Thoracic Surgery, The Second Hospital of Jilin University, 218 Ziqiang Street, Changchun, 130041, Jilin, China

    Li Qin, Guangxin Zhang, Peiyan Hua & Chengyan Jin

Authors
  1. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baihong Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin Chai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guangxin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peiyan Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chengyan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baihong Chi.

Ethics declarations

Conflict of interest

The author reports no conflict of interest in this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, L., Chi, B., Chai, J. et al. LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p. Mol Biotechnol 63, 933–940 (2021). https://doi.org/10.1007/s12033-021-00351-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12033-021-00351-6

Keywords

Search

Navigation